Due to increasing popularity of omega-3s, innovations are churning out to meet the special needs of every consumer. In the spirit of those innovations, DuPont (Wilmington, DE) recently announced the launch of New Harvest, a yeast source of eicosapentaenoic acid (EPA) that the company says is the market’s first fish-free, vegetarian EPA product.
Due to increasing popularity of omega-3s, innovations are churning out to meet the special needs of every consumer. In the spirit of those innovations, DuPont (Wilmington, DE) recently announced the launch of New Harvest, a yeast source of eicosapentaenoic acid (EPA) that the company says is the market’s first fish-free, vegetarian EPA product.
While consumers are becoming increasingly familiar with vegetarian sources of docosahexaenoic (DHA) omega-3, a vegetarian source of EPA omega-3 further closes the gap towards a vegetarian-friendly omega-3 market.
New Harvest’s primary selling points are “heart health” and “emotional well-being benefits” from a fish-free EPA source.
“Whether you’re a vegetarian or not, a large population is looking for a non-fish alternative, right now,” New Harvest marketing manager Kathryn Lee told Nutritional Outlook. “There’s a lot of science to back the benefits of omega-3s and now, with New Harvest, consumers can get the direct benefits of EPA omega-3 from a non-fish source.”
Lee says New Harvest’s fermentation process is much like the process involved with beer. The yeast feeds on sugar to produce EPA oil, and that EPA-rich oil is then separated from the yeast and encapsulated into a soft gel.
In a DuPont-funded survey of 2500 consumers ages 18 and older, 69% of those surveyed agreed that omega-3s are important to maintaining good health, but only 10% reported eating fatty fish at least twice a week.
With its market partner Futurebiotics (Hauppauge, NY), New Harvest is now available through GNC retail stores across the country.
For more information, click here.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.